Catalent Inc Stock News

Catalent stock moved higher on Thursday on reports that activist investor Elliot Investment Management has taken a significant stake in the company. Shares of the contract drugmaker had added 4% at US

Yahoo Finance Live's Diane King Hall and Julie Hyman report on Catalent stock as Elliott takes stake in the company.

Catalent (NYSE: CTLT ) stock is on the move Thursday as investors react to activist investor Elliott Investment taking a stake in the drug-making company. Specific details of the stake Elliott Investm

The activist is pushing for a shake-up of the contract drug manufacturer's board.

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock?

Catalent's (CTLT) drug manufacturing facility in Indiana faces problems, which is linked to FDA's rejection of Regeneron's eye drug application. This is the latest in a string of quality control issue

Difficulties at the contract manufacturer's site were apparently the reason for a drug's rejection by the FDA. That drug, a more potent form of eye medication Eylea, is made by biotech Regeneron Pharm

Although the revenue and EPS for Catalent (CTLT) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street

Catalent, Inc. (NYSE:CTLT ) Q3 2023 Earnings Conference Call June 12, 2023 8:15 AM ET Company Participants Paul Surdez - Vice President, Investor Relations Alessandro Maselli - President and Chief Exe

U.S. equities were up at midday on Monday, June 12, 2023 amid optimism the Fed will pause its rate hike cycle.

Catalent (CTLT) records lower revenues in both segments in third-quarter fiscal 2023, resulting in overall soft performance.

Catalent shares rose by double digits on Monday after the contract drug maker reported a third-quarter fiscal 2023 revenue beat, despite swinging to a loss and slashing its fiscal 2023 outlook for sal

Catalent reports an adjusted loss of 9 cents a share in its fiscal third quarter on revenue of $1.04 billion.

Catalent (CTLT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to earnings of $1.04 per share a year ago.

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will release financ